Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients
NCT ID: NCT02818465
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2015-03-30
2017-11-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determinants of Vascular Calcification in Chronic Renal Failure : Impact of Pyrophosphate Levels After Renal Transplantation
NCT03462238
CKD Cachexia and Gut Microbiome
NCT06986265
AGE - Functional Reserve
NCT02695251
Intra Individual Evaluation of Uremic Toxin Levels in Hemodialysed Patients
NCT02480699
Development of a Decision-making Aid for Referring Severe Kidney Injury Patients for Nephrology Consultations
NCT03192189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Vascular calcifications by Xray
Vascular calcifications by tomodentimetry
Blood sample withdrawn
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vascular calcifications by Xray
Vascular calcifications by tomodentimetry
Blood sample withdrawn
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hemodialysis for more than 3 months
* Have agreed to participate in research
* Affiliated to a social security scheme
* major
Exclusion Criteria
* Protected by law .
* minors
* pregnant women
* Matt or pigmented skin because the skin hyperpigmentation interfere with reading the skin fluorescence giving falsely elevated values .
* Having an aneurysm of the abdominal aorta known
* Suffering from a progressive neoplastic disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu de Reims
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Belmokhtar K, Ortillon J, Jaisson S, Massy ZA, Boulagnon Rombi C, Doue M, Maurice P, Fritz G, Gillery P, Schmidt AM, Rieu P, Toure F. Receptor for advanced glycation end products: a key molecule in the genesis of chronic kidney disease vascular calcification and a potential modulator of sodium phosphate co-transporter PIT-1 expression. Nephrol Dial Transplant. 2019 Dec 1;34(12):2018-2030. doi: 10.1093/ndt/gfz012.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR14037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.